
RANI Stock Forecast & Price Target
RANI Analyst Ratings
Bulls say
Rani Therapeutics Holdings Inc. has developed the proprietary RaniPill capsule, which aims to provide an innovative oral delivery method for biologics, thus offering a substantial improvement over traditional injection methods. The company is well-capitalized with financial resources extending through 2028, allowing for continued investment in its internal pipeline, including promising data from its RT-114 candidate, which shows favorable bioavailability and tolerability. Additionally, the increasing M&A activity in the oral delivery and obesity therapy space further enhances Rani Therapeutics' market potential and investor interest in the company's growth trajectory.
Bears say
Rani Therapeutics Holdings Inc faces significant challenges that contribute to a negative outlook on its stock, including potential limitations in gaining market share and the pressure of unfavorable pricing upon market entry. The company has experienced management turnover, which may disrupt clinical development efforts and negatively impact overall share performance. Additionally, concerns surrounding FDA approval for key devices, market adoption of the RaniPill technology, and a recent capital raise leading to share dilution further complicate the financial landscape for Rani Therapeutics.
This aggregate rating is based on analysts' research of Rani Therapeutics Holdings and is not a guaranteed prediction by Public.com or investment advice.
RANI Analyst Forecast & Price Prediction
Start investing in RANI
Order type
Buy in
Order amount
Est. shares
0 shares